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Goals:  
The goal of this article is to provide a review of 
available evidence for safe prescribing in older 
adults and recommend medication therapies 
based on anticipated 
pharmacokinetic/physiologic changes in this 
population. 
 
Learning Objectives:  
Upon completion of this article, the learner 
should be able to: 
1. Describe the physiologic and 
pharmacokinetic changes of aging that 
impact drug therapy and dosing. 
2. Identify the medications or medication 
classes included on the Beer’s Criteria 
3. Recognize the medications on the 
STOPP/START lists. 
4. Compare and contrast different 
methods of identifying potentially 
inappropriate medications for the 
elderly patients 
5. Discuss the pharmacist’s role in and 
approach to medication management 
for the older persons. 
 
 
ACPE UAN: 0120-0000-13-206-H04-P 
1.5 Contact Hours (0.15 CEU’s) 
This is a knowledge based activity 
See end or article for CE details. 
 
Target Audience: Pharmacists 
Faculty disclosure: The faculty have no conflicts 
of interest to disclose. 
 
 
Definitions 
1. Older adults are persons over the age 
of 65 years.  Also referred to as elderly 
or geriatric. 
2. Potentially inappropriate medications 
(PIMs) are drugs that have unfavorable 
benefit-to-risk ratio when safer or 
equally effective alternatives are 
available.1-3 
3. Implicit criteria use the entire clinical 
picture when assessing the 
appropriateness of a medication.  The 
benefit of implicit criteria is the 
specificity for each patient.  However, 
clinical judgment is needed and this can 
vary between practitioners.  Implicit 
criteria are typically not used in clinical 
trials due to the low inter-rater 
reliability.1,2 
4. Explicit criteria are created based on 
specific drugs or drug-related triggers.  
Unlike implicit criteria, explicit criteria 
can be used easily in clinical trials 
because of the high degree of inter-
rater reliability.  Most of the tools used 
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to identify PIMs in the elderly are 
explicit criteria.1,2  The Beers list was the 
first explicit criteria developed for 
identifying PIMs in the elderly. 
Introduction 
 
Elderly patients are at a higher risk of 
developing adverse drug reactions (ADRs) 
compared to their younger counterparts.4,5   
The most important risk factor for the 
occurrence of ADRs in the elderly is the use of 
PIMs.6  A recent study found that the use of 
PIMS in the elderly was associated with 7.2 
billion dollars in healthcare costs in 2001.5  For 
every dollar elderly patients spend on 
medications, an additional dollar is spent to 
manage ADRs with PIMs.7  PIMS are also 
associated with impaired physical performance 
and increased rate of hospitalizations in elderly 
patients living in the community.8,9 
 
Older adults are at an increased risk for ADRs 
due to polypharmacy and changes in their 
pharmacokinetic and pharmacodynamic 
profiles.  Currently, patients over the age of 65 
comprise approximately 12% of the total 
population in the United States.  However, they 
consume one-third of the prescription and one-
half of the over-the-counter medications.5,10     
By the year 2030, this population is expected to 
grow to 71 million, or 20% of the total United 
States (US) population.11  Elderly patients take 
on average five prescriptions and about 50% of  
this population experiences polypharmacy.6  As 
this subset of the population grows, 
pharmacists practicing in community, hospital 
and long-term care settings will have increased 
opportunities to optimize medication regimens 
and  prevent ADRs in these at risk patients. 
Anticipating ADRs is not only aimed at 
preventing bothersome side effects but also 
decreasing mortality.  It has been shown that up 
to 44% of fatal, life threatening or serious ADRs 
in the nursing home may be preventable.12 
 
Physiologic Changes  
There are several obvious physical changes 
associated with aging, yet those that cannot be 
assessed visually can have an important impact 
on drug therapy selection.  After age 30, renal 
function declines approximately 10% per 
decade of life.10   For those living into their 80s, 
renal function can be difficult to properly 
estimate based on lower lean body mass.  The 
importance of evaluating risk versus benefit 
with medication selection is imperative in older 
adults. 
 
Cardiovascular changes in the geriatric 
population are important to appreciate when 
establishing medication goals and anticipating 
adverse effects.  Stiffening of the arteries seen 
with aging, specifically the aorta, can increase 
the likelihood of isolated systolic hypertension.  
Lack of response to pressure changes in the 
arteries results in decreased vasoconstriction as 
compared to a normal baroreceptor reflex seen 
in a healthy younger adult population.13  This 
change predisposes the elderly to orthostatic 
hypotension and consequently, falls.  
Ambulation status of patients should be 
considered before initiating medications 
associated with a high incidence of orthostatic 
hypotension. 
 
Sensory changes in the older adult may 
complicate medication monitoring.  High 
frequency sounds such as a woman’s voice are 
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the first to be lost with age-related hearing loss.  
Cerumen tends to be drier in the elderly 
predisposing this population to impaction and 
consequently hearing loss.  The auditory 
changes can be perceived as signs of cognitive 
impairment.  Older adults may also suffer from 
vision changes such as decreased depth 
perception and increased time to accommodate 
to changes in lighting.14  Vision changes as 
described may increase risk of falls, highlighting 
the need for environments free of fall or 
tripping hazards.  Sensory changes associated 
with aging and their consequences should be 
considered to avoid additive effects with 
medication use.  Anticholinergic side effects 
such as those seen with over the counter 
medications like diphenhydramine can lead to 
confusion and blurred vision.  These side effects 
cannot only endanger patients but also present 
a challenge when assessing patients for 
diagnostic purposes.  In addition to vision and 
hearing changes, dexterity impairment in the 
hands associated with arthritis may make 
medication adherence a challenge.  Such 
patients may benefit from medication 
organizers and prescription vials with large, 
easy to open lids. 
 
Pharmacokinetics and Pharmacodynamics  
 
Changes in absorption, distribution, metabolism 
and elimination (ADME) may predispose elderly 
patients to drug toxicities. (Table 1)  In most 
older adults without a history of gastrointestinal 
disease, absorption is the least affected ADME 
parameter.4,5,10,15  Decreased gastrointestinal 
motility may retard absorption of medications 
but overall absorption remains unchanged.  
Decreased total body water results in a smaller 
volume of distribution for hydrophilic 
medication (e.g.,. lithium and aminoglycosides), 
supporting the need for smaller initial doses of 
these agents.  Lipophilic medications (e.g.,. 
diazepam and amiodarone) may accumulate 
due to an increase in adipose tissue; therefore, 
smaller doses or less frequent dosing may be 
preferred.10  First pass metabolism is decreased  
in the older adult resulting in an increased 
bioavailability of medications such as morphine. 
While usage of morphine is not avoided in older 
adults, conservative initial dosing addresses any 
changes that may occur with normal aging.  A 
decline in cytochrome P450 activity should be 
anticipated when selecting medications in 
geriatric patients. However, all medications 
undergoing Phase I metabolism may not be 
affected based on variability in isoenzyme 
groups.  A decrease in CYP 2 C19 has been 
shown, but consistent changes in CYP 2D6 have 
not been found.  In addition, these changes 
have varied based on overall health status of 
the older adults studied. Changes in phase II 
metabolism should not be anticipated.  As 
mentioned previously, elimination is affected by 
an age related decline in kidney function.  
Lower lean body mass may result in inaccurate 
interpretation of serum creatinine.  When 
estimating creatinine clearance based on 
Cockroft Gault, some clinicians round the serum 
creatinine to 1 to account for lower lean body 
mass in the older adult population.  This 
practice may underestimate clearance in 
healthy, ambulatory older patients16 resulting in 
patients receiving lower medication dosages or 
not receiving medication at all. (Figures 1 and 2) 
 
Pharmacodynamic differences in the older adult 
are not well understood and vary from patient 
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to patient.  Because of this, medication changes 
should be directed by patient response.  
Pharmacodynamic changes in the older adult 
may decrease effectiveness and increase 
toxicity associated with medication use.4,5,15  A 
lack or decreased response to beta blockers, 
and short and long acting beta-2 agonists may 
correlate with decreased affinity at the beta 
receptor in the elderly. 15  Morphine use in the 
geriatric patient is associated with an increased 
analgesic effect without changes in the risk for 
lower respiratory depression.15  Lower doses of 
warfarin are often needed to achieve 
therapeutic International Normalized Ratios 
(INRs) in older adults.  One study showed that 
the average weekly warfarin dose needed 
decreased by 0.4 mg for every year of age 
greater than 80.17  While older patients may 
require larger doses of furosemide to achieve 
the same diuresis as younger patients, they are 
prone to the electrolyte changes associated 
with loop diuretics.15  Elderly patients are more 
likely to experience the adverse effects 
associated with anticholinergic medications, 
even those with a low anticholinergic burden 
(e.g.,. loperamide, cimetidine).   More 
importantly, the level of impairment due to 
anticholinergic side effects is additive when 
multiple medications with these properties are 
used in combination.   
 
Table 1 
Pharmacokinetic 
Parameter 
Physiological 
Parameter 
Changes in the Older Adult 
Absorption Gastric acid production Least affected; May see lower acid 
production in patient with history of 
gastrointestinal disease   
Distribution 
  
  
Body fat  Increased Vd of lipid soluble drugs 
due to increased body fat 
Total body water  Decreased Vd of water soluble drugs 
due to decreased total body water 
Serum albumin  May see higher concentrations of 
unbound drug in highly protein 
bound drugs specifically in those 
patients with poor nutrition or low 
body weight 
Metabolism 
  
  
Liver mass and hepatic 
blood flow  
Decreased blood flow and decreased 
extraction via first pass metabolism 
Phase I reactions Anticipate decrease in all phase 1 
reactions; Anticipate more of a 
decline in CYP2C19 than in CYP2D6 
Phase II reactions No significant decrease 
Elimination Glomerular filtration 
rate  
Decreased; Most affected 
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Figure 1: A general approach that should be taken prior to rounding a serum creatinine to estimate a 
creatinine clearance.   
 Approach renal dosage adjustments in the geriatric patient considering overall health status of each 
individual patient. 
 Low albumin related to poor nutrition may result in lower serum creatinine values based on lower 
creatinine production.  This may lead pharmacist to assess patient’s muscle mass and therefore 
accuracy of creatinine clearance when using serum creatinine. 
 If a patient appears to have a relatively normal muscle mass for their age, the measured serum 
creatinine value should be used to calculate the estimated creatinine clearance.   
 Alternatively If a patient appears thin, frail or to have low muscle mass, the serum creatinine may be 
less reliable when estimating creatinine clearance.  In this case, the pharmacist needs to assess the 
risk versus the benefit of medication use.  The risk of toxicities outside of the therapeutic index of 
medication in addition to the acuity of illness should be considered for all therapies.  If a decision is 
made to round the creatinine to 1.0 when estimating the clearance, consequences of underdosing 
should be considered.   
 
Figure2:   
Patient Scenario: KL is an 92 yo female residing in Florida.  She walks around her senior living community 
for 30 minutes each morning with her husband.  Her height is 5’2” and her weight is 132 pounds.  Her 
most recent creatinine was 0.8 mg/dL. Patient has a penicillin allergy and has experienced confusion 
when taking quinolone antibiotics in the past. What dosage of sulfamethoxazole/trimethoprim would 
you recommend to treat a urinary tract infection in this patient? 
 CrCl calculated using 0.8 mg/dL = 36 ml/min   
 CrCl calculated rounding to 1.0 mg/dL = 28 ml/min 
Dosing Recommendations for Sulfamethoxazole/Trimethoprim: 
 CrCl > 30 ml/min: No dosage adjustment needed 
 CrCl 15-30 ml/min: Reduce dose by 50% 
 
Literature Review  
 
Beers Criteria  
In 1991 a group of geriatric practitioners led by 
the late Mark Beers, MD developed consensus 
guidelines known as the Beers criteria.3  These 
guidelines were originally intended to guide 
safe medication use in the sickest elderly 
population, nursing home residents.  The Beers 
criteria were updated in 1997, 2003 and most 
recently in 2012.  The 2012 updates were 
completed in collaboration with the American 
Geriatrics Society (AGS) and this update was 
designated for use in all patients over 65 years 
of age.  The current criteria are graded 
according to quality (high, moderate, low) and 
strength (strong, weak, insufficient) of 
recommendation evidence.  The Beers criteria 
are intended to improve care in older adults by 
reducing risk of exposure to PIMs.  The 2012 
criteria designate 38 individual medications or 
medication classes as PIMS with a 
recommendation for avoidance.  Fourteen 
diseases and PIMs based on drug-disease or 
INDIANA PHARMACISTS ALLIANCE (IPA) 
CONTINUING PHARMACY EUCATION (CPE) 
2013 
Article 9 
 
6  
 
drug-syndrome interaction are given an 
avoidance recommendation.  Five medications 
or groups of medications with similar 
mechanisms of action are designated as use 
with caution (Tables 2-5). 
 
The 38 medications or medication classes with a 
recommendation for avoidance are organized 
by organ system, therapeutic category or drug.  
The first category listed highlights the potential 
for adverse effects when using medications 
with anticholinergic properties.  Constipation, 
confusion and dry mouth are specifically 
addressed as reasons for avoidance with a list 
of first-generation antihistamines.  
Antispasmodics additionally are highlighted in 
the anticholinergic category with a 
recommendation for avoidance based on lack of 
efficacy.  Cardiovascular medications, 
specifically alpha1 blockers, central alpha 
agonists and nifedipine, are included due their 
risk of orthostatic hypotension.  The central 
nervous system category identifies first and 
second generation antipsychotics and their 
ability to increase the risk of stroke and 
mortality in patients with dementia.  
Additionally, short acting (e.g.,. alprazolam, 
lorazepam) and long acting (e.g.,. diazepam, 
chlordiazepoxide) anxiolytics are given an 
avoidance recommendation with falls and 
cognitive impairment being listed among other 
rationale.   
 
The 14 disease/conditions and PIMS to avoid 
include several examples of adverse effects 
associated with anticholinergic medication use 
in addition to increased medication sensitivity 
based on pharmacodynamic changes in the 
elderly population.  In patients with delirium, 
cognitive impairment, chronic constipation and 
benign prostatic hyperplasia, anticholinergics 
are given an avoidance recommendation based 
on their potential to worsen symptoms 
associated with these conditions.  Peripheral 
alpha blockers and tertiary tricyclic 
antidepressants are recommended to be 
avoided in patients with syncope based on their 
ability to cause orthostatic hypotension.   
 
The five categories of medication designated as 
“to be used with caution in older adults” are 
associated with an increased risk of adverse 
effects or lack of evidence of usefulness in the 
elderly population.  Aspirin is given a use with 
caution recommendation for primary 
prevention based of lack of evidence in patients 
80 and older.  Dabigatran and prasugrel are 
included in this section based on a greater risk 
of bleeding in older adults. In addition, lack of 
safety and efficacy of dabigatran in creatinine 
clearance < 30 ml/min is addressed in the 
rationale.  Antipsychotics and antidepressants 
with serotonin receptor activity are included 
based on their association with hyponatremia.  
Lastly, the vasodilator class is included due to 
potential exacerbation of syncope in patients 
with a history of syncope.  While the cautionary 
recommendation regarding antipsychotics and 
antidepressants association with hyponatremia 
is given a strong strength of recommendation, 
all others in this section of Beers are given a 
weak strength of recommendation. 
 
STOPP/START  
The STOPP/START (Screening Tool of Older 
Persons’ Prescriptions /Screening Tool to Alert 
doctors to Right Treatment) criteria were 
developed by a consensus panel from the 
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United Kingdom and Ireland.18 The 
STOPP/START lists were created to be used 
across Europe for persons age 65 and older.  
The goal of the group was to create a tool with 
four characteristics:  comprehensive and valid 
list, based on current clinical evidence, reflect 
the consensus opinion of a multi-disciplinary 
panel and include drug-drug and drug-disease 
interactions.  Both lists are organized based on 
physiologic system affected by the particular 
drugs. 
 
The STOPP list includes sixty-five criteria from 
seven physiologic systems.  The physiologic 
systems included are as follows:  cardiovascular, 
central nervous system and psychotropic drugs, 
gastrointestinal, respiratory, musculoskeletal, 
urogenital and endocrine.  The list also includes 
drugs that adversely affect patients prone to 
falls, analgesic drugs and a statement on 
duplicate drug classes. Inclusion on the list in 
the physiologic systems is primarily due to four 
reasons:  increased risk for toxicity or disease 
exacerbation (Table 2), no evidence or 
indication for use (Table 3), safer, more 
effective alternatives available (Table 4) and 
increased risk for adverse drug reactions (Table 
5). 
 
The four most common medications or 
medication classes mentioned are aspirin, 
tricyclic antidepressants (TCAs), non-steroidal 
anti-inflammatory drugs (NSAIDs) and 
antimuscarinic drugs.  The most common drug 
listed in the cardiovascular system subsection is 
aspirin.  Use of aspirin in the elderly may be 
inappropriate in the following situations:  in 
combination with warfarin; in patients with a 
history of peptic ulcer disease; doses > 150 
mg/day; in patients with no history of coronary, 
cerebral, or peripheral vascular symptoms; or 
treating dizziness not attributed to 
cerebrovascular disease.  The use of aspirin in 
combination with warfarin and peptic ulcer 
disease is considered appropriate if given 
concomitantly with a histamine H2-receptor 
antagonist (H2RA) or proton pump inhibitor 
(PPI).  Tricyclic antidepressants (e.g.,. 
amitriptyline, imipramine, nortriptyline) are the 
most common medication class described in the 
central nervous system.   TCAs are potentially 
inappropriate when used in patients with 
dementia and glaucoma because of the risk of 
worsening cognitive impairment and 
exacerbating glaucoma, respectively.  TCAs may 
cause cardiac conductive abnormalities putting 
the patient at risk for arrhythmias and cause 
constipation.  Non-steroidal anti-inflammatory 
drugs (e.g.,. ibuprofen, naproxen, ketoprofen) 
are potentially inappropriate in the elderly 
because the use may exacerbate moderate to 
severe hypertension and heart failure.  Also the 
long term use in mild osteoarthritis may not be 
warranted and other analgesics, such as 
acetaminophen, are preferred for maintenance 
therapy.  The risk of gastrointestinal bleeding 
when using an NSAID without the use of a 
protective agent (H2RA or PPI) is addressed 
within this section.  Lastly, the most common 
medication class listed in the STOPP criteria is 
the antimuscarinic drugs (e.g.,. oxybutynin, 
tolterodine) in the urogenital system 
subcategory.  Antimuscarinics are associated 
with increased confusion and agitation in 
dementia, exacerbation of glaucoma, chronic 
constipation and prostatism. 
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The three subcategories of medications not 
listed as physiologic systems are drugs that 
affect patients with history of falls, analgesic 
drugs and duplicate classes.  The drugs 
identified as those that increase the risk of falls 
include benzodiazepines, neuroleptic drugs, 
first generation antihistamines, vasodilators and 
long term opiates.  All of these medications may 
cause excessive sedation, reduce sensorium and 
impair balance either through gait disturbances 
or postural hypotension.  The subcategory of 
analgesic drugs addresses the use of opiates, 
such as fentanyl or morphine, as first line for 
mild to moderate pain, and the adverse effect 
of constipation with opiate use more than 2 
weeks.  Lastly, the list includes a statement on 
the use of duplicate medications or drug classes 
and the recommendation to optimize one 
medication prior to addition of another agent. 
 
The START list is one of the first lists that 
describe medications that are likely to be 
beneficial to the patient that are commonly 
omitted.  Most lists in the past have been 
medications to exclude rather than ones to 
include.  Similar to the STOPP list, the START list 
is organized into six physiologic systems (Table 
6).  The list includes the consideration of aspirin 
and statin therapy for patients with coronary, 
cerebral or peripheral vascular disease.  Also, 
consideration is recommended for angiotensin 
converting enzyme inhibitors in patients with 
chronic heart failure and acute myocardial 
infarction.  The list also describes the inhaled 
therapies to use in mild to moderate and 
moderate to severe chronic obstructive 
pulmonary disease.  Lastly, the criteria 
describes preventative therapy with aspirin and 
statin therapy in patients with diabetes mellitus 
and concomitant major cardiovascular risk 
factors such as hypertension, 
hypercholesterolemia, and smoking. 
  
Comparison of Criteria  
 
The Beers criteria and STOPP/START criteria 
were developed based on target patient 
populations served by the authors of each 
guideline.  The most obvious difference 
between the criteria is the inclusion of the 
potential for errors of omission included within 
the START criteria.  While Beers has undergone 
several revisions since the original criteria were 
published, opportunities to address untreated 
or under-treated conditions have not been 
included.  
 
Appropriate lengths of therapy and drug 
combinations with similar side effects are 
exclusive to the STOPP criteria.  Beta blockers 
and verapamil are identified as a combination 
associated with risk of symptomatic heart block.  
Use of warfarin and aspirin in combination 
without an H2RA or a PPI is highlighted as a 
potential for increased risk of bleeding. In 
addition, appropriate length of therapy of 
warfarin for treatment of first, uncomplicated 
deep vein thrombosis and pulmonary embolism 
is emphasized with appropriate lengths not to 
exceed 6 and 12 months, respectively.  While 
inclusion of these lengths of therapy is 
important, the most recent CHEST guidelines 
include an even shorter length of therapy for 
first provoked deep vein thrombosis, 3 
months.19  While the medication combinations 
or inappropriate lengths of therapy can 
predispose patients to adverse effects, the 
general practice recommendations regarding 
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lengths of therapy and medication 
combinations were developed based on 
prescribing trends in Europe.  Many of the one-
sentence recommendation summaries included 
within STOPP do not provide specific patient 
information that should be taken into 
consideration when applying these 
recommendations.  As an example, a dose of 
prednisone 5 mg or greater would warrant 
screening and impact fracture risk per National 
Osteoporosis Foundation but is not specified in 
the START criteria. 
 
The Beers criteria do provide more specific 
details within recommendations.  Examples of 
generic drug entities associated with PIMS are 
listed as opposed to providing general drug 
classes associated with adverse effects, such as 
those included in STOPP.    Details regarding 
those patients at greatest risk of ADRs are listed 
to guide the clinician in determining 
appropriate therapy selection.  As an example, 
non-COX, selective NSAIDs are labeled as 
increasing risk of gastrointestinal bleeding and 
peptic ulcer disease in high risk groups.  High 
risk groups are further explained as those older 
than 75 years old, receiving corticosteroids, 
receiving anticoagulants, or receiving 
antiplatelet medications. Within this 
recommendation, proton pump inhibitors and 
misoprostol are included as medications that 
reduce but do not eliminate risk.  The details 
provided in Beers help guide safe medication in 
the United States based on specifics included 
within clinical practice recommendations used 
within the US.  This risk stratification is not fully 
outlined in STOPP. 
 
Table 2:  Increased risk for disease exacerbation or toxicity  
Criteria Inclusion: Beers (B) STOPP (S)  Comments 
Cardiovascular Criteria -STOPP recommends PPI or H2RA 
with aspirin use and PUD history. 
Beers expands upon STOPP and  
recommends avoiding aspirin doses  
> 325 mg/day unless other  
alternatives are not effective 
-STOPP and Beers explain 
increased risk of digoxin toxicity with  
renal impairment. Beers includes  
explanation of lack of benefit of  
doses of digoxin > 125 mcg/day in  
heart failure. 
Alpha1 blockers and syncope/orthostasis B 
Aspirin and peptic ulcer disease (PUD) B,S 
Calcium channel blockers and chronic constipation B,S 
Cilostazol and heart failure B 
Digoxin > 125 mcg/day B,S 
Diltiazem or verapamil and NYHA class III or IV heart failure B,S 
Dronedarone and heart failure B 
Non selective beta blockers and chronic obstructive 
pulmonary disease 
S 
Pioglitazone or rosiglitazone and heart failure B 
Thiazide diuretic and gout S 
Central nervous system and psychotropic drugs -Beers specifies tertiary TCA’s 
(amitriptyline, clomipramine, imipramine, 
doxepin > 6mg/day) only as causing 
constipations and syncope. In addition, 
the safety of doxepin at doses < 6 mg/day 
is noted as being comparable to placebo.  
Acetylcholinesterase inhibitors and syncope B 
Antipsychotics and dementia (stroke) B 
Benzodiazepines and delirium B 
Long term neuroleptics and parkinsonisms S 
SSSRIs and hyponatremia S 
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TCAs and constipation  B,S All other TCA related side effects listed 
within Beers encompass the entire class.  
- STOPP does not specifically list any 
medications within the TCA class.  
TCAs and delirium B 
TCAs and dementia  B,S 
TCAs and glaucoma S 
TCAs and syncope B 
TCAs and urinary retention B,S 
Endocrine -Beers specifically states that oral and 
transdermal estrogen may aggravate 
urinary incontinence, excluding 
intravaginal application. 
Androgens and prostate cancer B 
Corticosteroids and delirium B 
Estrogens and breast cancer or venous thromboembolism S 
Estrogens and urinary incontinence B 
Gastrointestinal  -Anticholinergic antispasmodics drugs 
listed in Beers but not in STOPP 
-Beers does not specifically address length 
of use in evidence supporting cognitive 
impairment with H2 receptor antagonists 
Anticholinergic antispasmodics and chronic constipation B,S 
Diphenoxylate, loperamide or codeine phosphate and 
severe infective gastroenteritis 
S 
H2RAs and delirium/dementia B 
Prochlorperazine or metoclopramide and parkinsonism B,S 
Musculoskeletal  -In contrast to STOPP criteria, Beers 
lists risk factors for GI bleeding with 
NSAID’s: age>75 yo, oral/parenteral 
corticosteroid use, anticoagulant 
use or antiplatelet use. Beers further  
explains trends with longer use. 
NSAIDs and chronic renal failure B,S 
NSAIDs and Heart failure B,S 
NSAIDs and moderate-severe hypertension S 
NSAIDs and PUD, GI bleeding B,S 
Urogenital -In contrast to STOPP criteria, Beers 
excludes bladder antimuscarinics from the 
anticholinergic drugs that should be 
avoided with benign prostatic hyperplasia 
Antimuscarinic and chronic constipation B,S 
Antimuscarinic and chronic prostatism S 
Antimuscarinic and glaucoma S 
Bladder antimuscarinic and dementia B,S 
 
 
Table 3:  No evidence or indication for use 
Criteria Inclusion: Beers (B) STOPP (S) Criteria 
Cardiovascular 
Aspirin without history of coronary, cerebral or peripheral vascular 
symptoms  
S 
 
Aspirin to treat dizziness not due to cerebrovascular disease S 
Dipyridamole as monotherapy for cardiovascular secondary prevention B,S 
Loop diuretics and ankle edema not due to clinical heart failure S 
Warfarin for first uncomplicated DVT for longer than 6 months S 
Warfarin for first uncomplicated PE  for longer than 12 months S 
Central Nervous system and psychotropic drugs 
Ergot mesylates B 
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Gastrointestinal 
PPI for PUD at full therapeutic doses for > 8 weeks S 
Urogenital 
Alpha blockers for long term urinary catheter S 
 
 
Table 4:  Increased risk for adverse drug reactions 
Criteria Inclusion: Beers (B) STOPP (S) Criteria 
Cardiovascular 
Aspirin >150 mg/day (bleeding) S 
Aspirin, clopidogrel, dipyridamole or warfarin with bleeding disorder 
(bleeding) 
S 
 
Aspirin and warfarin in combination without H2RA or PPI (bleeding) S 
BB and verapamil (heart block) S 
Central alpha agonists (CNS effects) B 
Dipyridamole, short acting (orthostatic hypotension) B 
Nifedipine IR (hypotension) B 
Spironolactone > 25 mg/day (hyperkalemia) B 
Central Nervous system and psychotropic drugs 
Anticholinergics to treat EPS (anticholinergic effects) B,S 
Barbiturates (physical dependence) B 
Long term, long acting BZD B,S 
Non-BZD hypnotics B 
Phenothiazines and persons with epilepsy (seizures) B,S 
Prolonged use of first generation antihistamines (anticholinergic effects) B,S 
TCA and cardiac conductive abnormalities (pro-arrhythmic) B,S 
TCA (sedation, orthostatic hypotension) B 
TCA and opiate or CCB (constipation) S 
Gastrointestinal 
Diphenoxylate, loperamide or codeine phosphate in diarrhea of unknown 
cause (delayed diagnosis, toxic megacolon) 
S 
 
Musculoskeletal 
Long term corticosteroids as monotherapy for RA or OA (corticosteroid 
systemic side effects) 
S 
 
Pentazocine (CNS effects) B 
Skeletal muscle relaxants (anticholinergic effects and sedation) B 
Warfarin and NSAID (bleeding) S 
Urogenital 
Alpha blockers (urinary frequency or worsening incontinence, orthostasis) B,S 
Nitrofurantoin (pulmonary toxicity) B 
Endocrine 
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BB and Diabetes (mask hypoglycemic symptoms) S 
Estrogens without progestin with intact uterus (endometrial cancer) B,S 
Sliding scale insulin (hypoglycemia) B 
Sulfonylureas: Glibenclamide [glyburide] or chlorpropamide 
(hypoglycemia) 
B,S 
Urinary antispasmodics (anticholinergic effects) B 
 
 
 
Table 5:  Safer, more effective alternative option 
Criteria Inclusion: Beers (B) STOPP (S) Criteria 
Cardiovascular 
Antiarrhythmic drugs (Class Ia, Ic, III) B 
Disopyramide B 
Dronedarone B 
Loop diuretic as first line hypertension monotherapy S 
Ticlopidine B 
Respiratory 
Systemic corticosteroids in moderate-to-severe COPD S 
Theophylline as monotherapy in COPD S 
Musculoskeletal 
Long term NSAID for mild OA S 
Long term NSAID or colchicine for chronic gout S 
Meperidine B 
Urogenital 
Nitrofurantoin (CrCl <60 ml/min) B 
Endocrine 
Desiccated thyroid B 
Megestrol B 
 
Table 6:  START criteria:  should be considered for people ≥ 65 years of age with the following 
conditions, where no contraindications exist 
Cardiovascular 
Warfarin and Atrial Fibrillation Aspirin and atrial fibrillation with contraindication 
to warfarin 
Aspirin or clopidogrel and atherosclerotic 
coronary, cerebral or peripheral vascular disease in 
patients with sinus rhythm 
Anti-hypertensive therapy and SBP > 160 mmHg 
Statin therapy and coronary, cerebral or peripheral 
vascular disease 
ACEI and chronic heart failure 
ACEI and acute MI BB and chronic stable angina 
Respiratory system 
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Inhaled B2 agonist or anticholinergic for mild to 
moderate COPD 
Inhaled corticosteroid for moderate to severe 
COPD 
Home O2 with chronic type 1 or 2 respiratory 
failure 
 
Central nervous system 
L-Dopa and Parkinson’s disease with functional 
impairment and resultant disability 
Antidepressant and moderate-severe depressive 
symptoms lasting 3 months 
Gastrointestinal system 
PPI and severe GERD Fiber supplementation and chronic symptomatic 
diverticular disease with constipation 
Musculoskeletal system 
DMARD with active moderate-severe RA Bisphosphonates and maintenance oral 
corticosteroid therapy 
Calcium and vitamin D supplement and 
osteoporosis 
 
Endocrine system 
Metformin and T2DM with or without metabolic 
syndrome 
ACEI or ARB and diabetes with nephropathy 
Antiplatelet and DM with one or more major 
cardiovascular risk factors* 
Statin therapy and DM with one or more 
cardiovascular risk factors* 
*Major cardiovascular risk factors:  hypertension, hypercholesterolemia, smoking history 
 
Abbreviations used in Tables 1-5:  ACEI: 
angiotensin converting enzyme inhibitor; ARB: 
angiotensin receptor blocker; BB: beta blocker; 
BZD: benzodiazepine; CCB: calcium channel 
blocker; COPD: chronic obstructive pulmonary 
disease; CrCl:  creatinine clearance; DM: 
diabetes mellitus; DMARD: disease modifying 
anti-rheumatic drug; DVT: deep vein 
thrombosis; EPS: extrapyramidal symptoms; 
GERD: gastro-esophageal reflux disease; GI: 
gastrointestinal; H2RA: histamine-2 receptor 
antagonist; mcg: microgram; MI: myocardial 
infarction; NSAID: non-steroidal anti-
inflammatory drug; NYHA: New York Heart 
Association; O2: oxygen; OA: osteoarthritis; PE: 
pulmonary embolism; PPI: proton pump 
inhibitor; PUD: peptic ulcer disease; RA: 
rheumatoid arthritis; SBP: systolic blood 
pressure; SSRI: selective serotonin reuptake 
inhibitor; T2DM: type 2 diabetes mellitus; TCA: 
tricyclic antidepressant 
 
Other Tools to Identify PIMs 
 
The Beers and the STOPP/START criteria are the 
most commonly used recommendations that 
identify PIMs in the elderly.  Other lists have 
been developed in Canada, France, Australia 
and Norway.2  The first criteria after the Beers 
list came from Canada and is cited as the 
Canadian Criteria.20  This criteria was developed 
based on limitations of the Beers criteria that 
were identified by the authors.  In comparison 
to the 1997 Beers criteria, the Canadian Criteria 
includes more drug-drug and drug-disease 
interactions.  This list has not been updated 
since its origination in 1997.  Based on the initial 
criteria from Canada, a group of separate 
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authors developed The Improving Prescribing in 
the Elderly Tool (IPET) in 2000.21  IPET includes 
fourteen specific criteria and only includes drug-
disease interactions.  The narrow spectrum of 
interactions and limited number of criteria 
prohibits the global use of the IPET criteria. 
 
France was the first European country to 
develop criteria for prescribing for the elderly.  
The group of experts that developed the French 
Consensus Panel List used the 1997 Beers 
criteria, the two Canadian criteria and practice 
guidelines from France to develop the thirty-
four item list.22  The list is organized into three 
categories:  unfavorable benefit to risk ratio, 
questionable efficacy, and the combination of 
the other two categories.  The majority of the 
criteria address the use of medications with 
anticholinergic properties.  One difference from 
previous criteria is that the French Consensus 
Panel List includes alternative medications to 
consider.   
 
The same year that STOPP/START was created, 
the Australians were developing a prescribing 
tool of their own.  The Australian Prescribing 
Indicators Tool was developed from combining 
the most common problems managed by 
general practitioners in Australia with the fifty 
most common medications prescribed, not 
using a consensus panel like previous lists.23  
The Australian Prescribing Indicators Tool was 
also one of the first lists to include implicit 
criteria.  The tool is organized by patient 
scenarios with specific footnotes and requires 
the physician use the list with an accompanying 
contraindication table.  The indicators are also 
described using the desired outcome instead of 
the inappropriate situation.  The complicated 
manner in which the scenarios must be 
interpreted may be a limiting factor for the 
broad use of the tool outside of Australia. 
 
The last explicit list that was created was the 
Norwegian General Practice (NORGEP) Criteria 
in 2009.24  The thirty-seven criteria are divided 
between two groups:  drugs or drug dosages 
and drug combinations considered potentially 
inappropriate.  Psychotropic medications are 
the most common drug class included in the 
NORGEP criteria.  The limitation to the use of 
this list outside of Norway, is the inclusion of 
medications not commonly used outside of the 
country and medications not limited to the 
elderly population.  
 
Application to Pharmacist and Medication 
Therapy Management 
 
The aging population in the United States is 
rapidly growing and is expected to almost 
double by the year 2030.  Pharmacists will have 
a greater exposure to this patient population in 
any setting.  This exposure leads to an increased 
opportunity to participate in the care of older 
adults.  Pharmacists need to be aware of 
potential physiologic changes while keeping in 
mind that the effect of these changes is not 
completely understood.  This should direct 
pharmacists to use conservative dosing in this 
patient population until individual response is 
identified.  It is imperative that pharmacists 
consider the whole patient in addition to the 
medication list when evaluating the 
appropriateness of specific medications based 
on the criteria discussed above.  The AGS has 
developed a document to guide healthcare 
practitioners in caring for the geriatric adult.  
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Some of the key points applicable to a 
pharmacist have been described in Figure three.  
Emphasis is placed on medication risk versus 
benefit in addition to patient preference 
regarding their overall healthcare.25  The AGS 
recommendations serve as a guideline to 
promote safe prescribing in the geriatric 
patient; however, practitioner evaluation of 
quality evidence is required to assure optimal 
medication therapy. 
 
 
 
 
 
 
 
 
  
Figure 3:  Key Factors to Consider When 
Managing a Geriatric Pharmacotherapy 
Regimen: 
 Specific requests of patient (generic vs. 
brand, once daily dosing, liquid vs. tablet) 
 Evidence available to support reaching 
outcomes tailored to the patient (living 
environment, co-morbidities and length of 
time to reach outcomes) 
 Drug properties and interactions 
(anticipated response based on physiologic 
and pharmacokinetic changes, interactions 
with multiple medications for multiple co-
morbidities) 
 Involve patient in risk versus benefit 
discussion of all medication therapy 
 Establish follow up, goals of therapy and 
educate on the importance of adherence to 
follow up 
 
 
The Pharmacists Education Foundation (PEF) is accredited by the Accreditation council for 
Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  To receive continuing 
pharmacy education (CPE) credit, pharmacists MUST COMPLETE AN ONLINE QUIZ AND EVALUATION 
FORM.  A score of 70% or above is required to receive CPE credit.  The link to the quiz can be accessed 
from the MEMBERS page of the IPA website at www.indianapharmacists.org.  This is a free service to IPA 
members in 2013. Initial release date 12/20/2013. Expiration Date:12/20/2016. Questions: Call IPA at 
(317) 634-4968.  
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INSTRUCTIONS: This page is intended to help participants REVIEW the quiz prior to submitting 
their answers online.  Please take the quiz online using the members section of the website. 
 
Geriatric Medication Therapy:  Weighing the Evidence versus Best Practice Questions 
 
 Which of the following is the most important risk factor for adverse drug reactions in the elderly? 
a. Polypharmacy 
b. Decreased absorption in the stomach 
c. Use of potentially inappropriate medications 
d. Stiffening of the arteries 
2. All of the following physiologic changes are associated with aging EXCEPT: 
a. Increased liver function tests 
b. Stiffening of the arteries 
c. Declining renal function 
d. Decreased depth perception 
3. Which of the following pharmacokinetic changes would you expect in older persons taking 
diazepam, a lipophilic medication? 
a. No changes 
b. Increased volume of distribution 
c. Decreased maximal concentration 
d. Shorter elimination half life 
4. In which of the following medications would you expect to see a pharmacodynamic changes in 
the elderly? 
a. Warfarin 
b. Lisinopril 
c. Donepezil 
d. Aspirin 
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5. AG is an 87 year old male who presents to his PCP for his annual visit.  His past medical history is 
significant for hypertension, diabetes and atrial fibrillation.  His current medications include:  
lisinopril, carvedilol, dabigatran and metformin.  According to the Beer’s Criteria, which of the 
following medications could be considered inappropriate? 
a. Lisinopril 
b. Carvedilol 
c. Dabigatran 
d. Metformin  
6. MD is an 81 year old female who presents to your pharmacy following her annual PCP visit.  Her 
past medical history is significant for dementia, hypothyroidism and hypertension.  Her current 
medication profile includes:  donepezil, levothyroxine, hydrochlorothiazide and lisinopril.  She 
presents a prescription to the pharmacy for amitriptyline 25 mg orally at bedtime for 
depression.  According to the STOPP/START criteria, which of the following is most appropriate? 
a. Fill the prescription as it is written 
b. Call the prescriber and recommend to increase the dose to 50 mg  
c. Call the prescriber and recommend to change to another antidepressant 
d. Call the prescriber and recommend to decrease the dose to 12.5 mg 
7. JT is a 92 year old male who presents to his cardiologist for a routine check-up.  His past cardiac 
history is significant for atrial fibrillation, heart failure, and peripheral vascular disease.  His 
medications include:  aspirin 325 mg orally daily, cilostazol 100 mg orally BID, diltiazem 320 mg 
ER PO daily and dronedarone 400 mg orally BID.  Which of the following medications is deemed 
potentially inappropriate by BOTH Beer’s criteria and STOPP/START list? 
a. Dronedarone 
b. Diltiazem 
c. Cilostazol  
d. Aspirin 
8. Which of the following statements is true regarding the gaps in the Beer’s Criteria as compared 
to the STOPP/START list? 
a. STOPP/START list includes potential errors of omission 
b. The Beer’s list includes duration of therapy 
c. The STOPP/START give more specific details within the recommendation 
d. The Beer’s list includes drug combinations to be avoided 
9. Of the following tools to identify potentially inappropriate medications, which one includes 
implicit criteria? 
a. Improving Prescribing in the Elderly Tool 
b. French Consensus Panel List 
c. Norwegian General Practice Criteria 
d. Australian Prescribing Indicators Tool 
10. When taking care of geriatric patients, pharmacists can do which of the following? 
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a. Recommend therapy strictly based on tools used to identify potentially inappropriate 
medications 
b. Use conservative dosing and titrate based on patient response 
c. Make no changes to their recommendations—there are no differences between older 
and younger adults 
Recommend all changes based on generalized pharmacodynamic and pharmacokinetic changes 
in the elderly 
